FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1970782429> ?p ?o ?g. }

• W1970782429 endingPage "215" @default.
• W1970782429 startingPage "211" @default.
• W1970782429 abstract "Background There has been little systematic study of “next-step” interventions for patients with generalized anxiety disorder (GAD) who remain symptomatic despite initial pharmacotherapy. We present one of the first randomized controlled trials for refractory GAD, comprising double blind augmentation with olanzapine or placebo for patients remaining symptomatic on fluoxetine. Methods Patients remaining symptomatic after 6 weeks of fluoxetine (20 mg/day) were randomized to 6 weeks of olanzapine (mean dose 8.7 ± 7.1 mg/day) or placebo augmentation. Results Twenty-four of 46 fluoxetine-treated patients were randomized. Olanzapine resulted in a greater proportion of treatment responders based on a Clinical Global Impression-Severity Scale (CGI-S) end point score of 1 or 2 (Fisher’s exact test [FET] p < .05) or a 50% reduction in Hamilton Anxiety Scale (HAMA-A) score (FET p < .05). There were no other statistically significant differences for olanzapine compared with placebo augmentation in outcome measures, though rates of remission (HAM-A ≤ 7) on olanzapine were higher at the level of a trend (FET, p = .1). Average weight gain for completers was greater with olanzapine than placebo augmentation (11.0 ± 5.1 vs. −0.7 ± 2.4 pounds: t = 6.32, p < .001). Conclusions Olanzapine may have a salutary effect on anxiety for some GAD patients remaining symptomatic despite initial serotonin selective reuptake inhibitor (SSRI) therapy, but the emergence of significant weight gain represents an important clinical consideration. There has been little systematic study of “next-step” interventions for patients with generalized anxiety disorder (GAD) who remain symptomatic despite initial pharmacotherapy. We present one of the first randomized controlled trials for refractory GAD, comprising double blind augmentation with olanzapine or placebo for patients remaining symptomatic on fluoxetine. Patients remaining symptomatic after 6 weeks of fluoxetine (20 mg/day) were randomized to 6 weeks of olanzapine (mean dose 8.7 ± 7.1 mg/day) or placebo augmentation. Twenty-four of 46 fluoxetine-treated patients were randomized. Olanzapine resulted in a greater proportion of treatment responders based on a Clinical Global Impression-Severity Scale (CGI-S) end point score of 1 or 2 (Fisher’s exact test [FET] p < .05) or a 50% reduction in Hamilton Anxiety Scale (HAMA-A) score (FET p < .05). There were no other statistically significant differences for olanzapine compared with placebo augmentation in outcome measures, though rates of remission (HAM-A ≤ 7) on olanzapine were higher at the level of a trend (FET, p = .1). Average weight gain for completers was greater with olanzapine than placebo augmentation (11.0 ± 5.1 vs. −0.7 ± 2.4 pounds: t = 6.32, p < .001). Olanzapine may have a salutary effect on anxiety for some GAD patients remaining symptomatic despite initial serotonin selective reuptake inhibitor (SSRI) therapy, but the emergence of significant weight gain represents an important clinical consideration." @default.
• W1970782429 created "2016-06-24" @default.
• W1970782429 creator A5018662404 @default.
• W1970782429 creator A5019050839 @default.
• W1970782429 creator A5042259286 @default.
• W1970782429 creator A5043205589 @default.
• W1970782429 creator A5049932530 @default.
• W1970782429 creator A5065137309 @default.
• W1970782429 creator A5065758533 @default.
• W1970782429 creator A5071835676 @default.
• W1970782429 date "2006-02-01" @default.
• W1970782429 modified "2023-10-18" @default.
• W1970782429 title "Olanzapine Augmentation of Fluoxetine for Refractory Generalized Anxiety Disorder: A Placebo Controlled Study" @default.
• W1970782429 cites W1963819725 @default.
• W1970782429 cites W1981272264 @default.
• W1970782429 cites W1983934794 @default.
• W1970782429 cites W1984770623 @default.
• W1970782429 cites W1984780761 @default.
• W1970782429 cites W1988405118 @default.
• W1970782429 cites W1992176680 @default.
• W1970782429 cites W1999689270 @default.
• W1970782429 cites W2037875799 @default.
• W1970782429 cites W2049025206 @default.
• W1970782429 cites W2049946828 @default.
• W1970782429 cites W2066030263 @default.
• W1970782429 cites W2069564992 @default.
• W1970782429 cites W2073712495 @default.
• W1970782429 cites W2077145937 @default.
• W1970782429 cites W2079314303 @default.
• W1970782429 cites W2080784754 @default.
• W1970782429 cites W2090191759 @default.
• W1970782429 cites W2091470293 @default.
• W1970782429 cites W2095549609 @default.
• W1970782429 cites W2114613490 @default.
• W1970782429 cites W2116042849 @default.
• W1970782429 cites W2127758000 @default.
• W1970782429 cites W2147782024 @default.
• W1970782429 cites W2159990726 @default.
• W1970782429 cites W2160070901 @default.
• W1970782429 cites W2165379748 @default.
• W1970782429 cites W2367662090 @default.
• W1970782429 cites W2414524681 @default.
• W1970782429 doi "https://doi.org/10.1016/j.biopsych.2005.07.005" @default.
• W1970782429 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16139813" @default.
• W1970782429 hasPublicationYear "2006" @default.
• W1970782429 type Work @default.
• W1970782429 sameAs 1970782429 @default.
• W1970782429 citedByCount "124" @default.
• W1970782429 countsByYear W19707824292012 @default.
• W1970782429 countsByYear W19707824292013 @default.
• W1970782429 countsByYear W19707824292014 @default.
• W1970782429 countsByYear W19707824292015 @default.
• W1970782429 countsByYear W19707824292016 @default.
• W1970782429 countsByYear W19707824292017 @default.
• W1970782429 countsByYear W19707824292018 @default.
• W1970782429 countsByYear W19707824292019 @default.
• W1970782429 countsByYear W19707824292020 @default.
• W1970782429 countsByYear W19707824292021 @default.
• W1970782429 countsByYear W19707824292022 @default.
• W1970782429 countsByYear W19707824292023 @default.
• W1970782429 crossrefType "journal-article" @default.
• W1970782429 hasAuthorship W1970782429A5018662404 @default.
• W1970782429 hasAuthorship W1970782429A5019050839 @default.
• W1970782429 hasAuthorship W1970782429A5042259286 @default.
• W1970782429 hasAuthorship W1970782429A5043205589 @default.
• W1970782429 hasAuthorship W1970782429A5049932530 @default.
• W1970782429 hasAuthorship W1970782429A5065137309 @default.
• W1970782429 hasAuthorship W1970782429A5065758533 @default.
• W1970782429 hasAuthorship W1970782429A5071835676 @default.
• W1970782429 hasConcept C118552586 @default.
• W1970782429 hasConcept C126322002 @default.
• W1970782429 hasConcept C142724271 @default.
• W1970782429 hasConcept C15744967 @default.
• W1970782429 hasConcept C168563851 @default.
• W1970782429 hasConcept C170493617 @default.
• W1970782429 hasConcept C204787440 @default.
• W1970782429 hasConcept C27081682 @default.
• W1970782429 hasConcept C2775864247 @default.
• W1970782429 hasConcept C2776000289 @default.
• W1970782429 hasConcept C2776134451 @default.
• W1970782429 hasConcept C2776412080 @default.
• W1970782429 hasConcept C2776619155 @default.
• W1970782429 hasConcept C2777669559 @default.
• W1970782429 hasConcept C2779177272 @default.
• W1970782429 hasConcept C2779911313 @default.
• W1970782429 hasConcept C2780092697 @default.
• W1970782429 hasConcept C558461103 @default.
• W1970782429 hasConcept C71924100 @default.
• W1970782429 hasConceptScore W1970782429C118552586 @default.
• W1970782429 hasConceptScore W1970782429C126322002 @default.
• W1970782429 hasConceptScore W1970782429C142724271 @default.
• W1970782429 hasConceptScore W1970782429C15744967 @default.
• W1970782429 hasConceptScore W1970782429C168563851 @default.
• W1970782429 hasConceptScore W1970782429C170493617 @default.
• W1970782429 hasConceptScore W1970782429C204787440 @default.
• W1970782429 hasConceptScore W1970782429C27081682 @default.
• W1970782429 hasConceptScore W1970782429C2775864247 @default.
• W1970782429 hasConceptScore W1970782429C2776000289 @default.

• next